About: ISG20 promotes local tumor immunity and contributes to poor survival in human glioma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: ISG20 promotes local tumor immunity and contributes to poor survival in human glioma Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	ISG20 promotes local tumor immunity and contributes to poor survival in human glioma
Creator	Wang, Zheng Wang, Yulin Liu, Xing Gao, Mengqi Guo, Zongze Li, Yiming Lin, Yi Wang, Zhiliang Zhang, Chuanbao
source	PMC
abstract	Recent evidence has confirmed that a mutation of the isocitrate dehydrogenase (IDH) gene occurs early in gliomagenesis and contributes to suppressed immunity. The present study aimed to determine the candidate genes associated with IDH mutation status that could serve as biomarkers of immune suppression for improved prognosis prediction. Clinical information and RNA-seq gene expression data were collected for 932 glioma samples from the CGGA and TCGA databases, and differentially expressed genes in both lower-grade glioma (LGG) and glioblastoma (GBM) samples were identified according to IDH mutation status. Only one gene, interferon-stimulated exonuclease gene 20 (ISG20), with reduced expression in IDH mutant tumors, demonstrated significant prognostic value. ISG20 expression level significantly increased with increasing tumor grade, and its high expression was associated with a poor clinical outcome. Moreover, increased ISG20 expression was associated with increased infiltration of monocyte-derived macrophages and neutrophils, and suppressed adaptive immune response. ISG20 expression was also positively correlated with PD-1, PD-L1, and CTLA4 expression, along with the levels of several chemokines. We conclude that ISG20 is a useful biomarker to identify IDH-mediated immune processes in glioma and may serve as a potential therapeutic target.
has issue date	2018-10-31(xsd:dateTime)
bibo:doi	10.1080/2162402x.2018.1534038
bibo:pmid	30713788
has license	cc-by-nc-nd
sha1sum (hex)	57b88add1645a89614742dc32b0e11922c5f37d2
schema:url	https://doi.org/10.1080/2162402x.2018.1534038
resource representing a document's title	ISG20 promotes local tumor immunity and contributes to poor survival in human glioma
has PubMed Central identifier	PMC6343791
has PubMed identifier	30713788
schema:publication	Oncoimmunology
resource representing a document's body	covid:57b88add1645a89614742dc32b0e11922c5f37d2#body_text
is schema:about of	named entity 'identify' named entity 'glioma' named entity 'glioma' named entity 'expression' named entity 'glioma' covid:arg/57b88add1645a89614742dc32b0e11922c5f37d2 named entity 'gene' named entity 'mutant' named entity 'processes' named entity 'identified' named entity 'neutrophils' named entity 'tumor grade' named entity 'PD-L1' named entity 'serve' named entity 'serve' named entity 'neutrophils' named entity 'mutation' named entity 'prognosis' named entity 'glioma' named entity 'gene expression data' named entity 'LGG' named entity 'IDH' named entity 'adaptive immune response' named entity 'IDH' named entity 'mutation' named entity 'tumor immunity' named entity 'chemokines' named entity 'inflammatory response' named entity 'tumor' named entity 'IFN' named entity 'monocytes' named entity 'glioma' named entity 'KEGG' named entity 'immunohistochemical staining' named entity 'monocyte' named entity 'immune response' named entity 'World Health Organization' named entity 'attractor' named entity 'CXCR6' named entity 'monocytes' named entity 'tumors' named entity 'hematoxylin' named entity 'microglia' named entity 'World Health Organization' named entity 'gene expression' named entity 'ISG20' named entity 'CCL2' named entity 'Cox regression' named entity 'ISG20' named entity 'precursor cell' named entity 'low-grade' named entity 'antitumor' named entity 'adaptive immune responses' named entity 'hazard ratio' named entity 'mutation' named entity 'CCL23' named entity 'tumor grade' named entity 'mutation' named entity 'gliomas' named entity 'immune cell' named entity 'glioma' named entity 'inflammation' named entity 'lymphocyte homing' named entity 'clinical outcomes' named entity 'ISG20' named entity 'tumors' named entity 'progenitor cells' named entity 'CD4' named entity 'prognostic factor' named entity 'S1C' named entity 'cytotoxic T lymphocyte' named entity 'peroxidase' named entity 'tumors'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software